Montalescot G, et al. Lancet 2009;373:723-31. Trial profile Montalescot G, et al. Lancet 2009;373:723-31.

Slides:

Advertisements

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,

Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)

Trial profile Mann JF et al. Lancet 2008;372:

TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,

Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.

Volume 386, Issue 9988, Pages (July 2015)

Volume 385, Issue 9985, Pages (June 2015)

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Impella 2.5® Device Is Associated with Improved Survival in AMICS

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

PAD Patients vs Post-ACS Patients:

Patient disposition for the double-blind study period.

The Safety and Efficacy of Full vs

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

Baseline characteristics of patients

Trial profile John A Dormandy et al. Lancet 2005;366:

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Becker RC, et al. Lancet 2009;373:919-28

David F. Katz et al. JACEP 2016;j.jacep

Giuseppe Boriani et al. JACEP 2016;2:

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Kaplan-Meier curves for overall survival (OS) probability.

Volume 385, Issue 9985, Pages (June 2015)

Enrollment and Outcomes

Kaplan-Meier survival curve demonstrating treatment duration of metformin and orlistat. Kaplan-Meier survival curve demonstrating treatment duration of.

Volume 2, Issue 5, Pages (May 2015)

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

David F. Katz et al. JACEP 2017;3:20-28

Baseline Characteristics of the Subjects

Flow of Patients Through the Trial

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Volume 12, Issue 8, Pages (August 2013)

Volume 2, Issue 10, Pages (October 2015)

Collet JP, et al. Lancet 2009;373:309-17

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Primary safety endpoint

Kaplan-Meier survival curve for unloader brace—Kaplan-Meier survival analysis demonstrated rapid conversion to TKR for the first 12 months, which then.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

RADIANCE 2 Study: Trial proﬁle

PROSPER: trial design

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Comparison of Baseline Characteristics by Primary End Point

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Baseline characteristics of study population

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Maxime Berthelot-Richer et al. JIMG 2016;9:

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier survival plot for primary endpoint of arthritis development. Kaplan-Meier survival plot for primary endpoint of arthritis development. Arthritis-free.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Kaplan-Meier curve for time until secondary surgery based on age at primary palate repair. Kaplan-Meier curve for time until secondary surgery based on.

Overall and recurrence-free survival.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Kaplan-Meier failure curves with development of RA stratified by depression exposure. Kaplan-Meier failure curves with development of RA stratified by.

Presentation transcript:

Montalescot G, et al. Lancet 2009;373:723-31

Trial profile Montalescot G, et al. Lancet 2009;373:723-31

Baseline characteristics of STEMI cohort, by drug allocation and type of PCI Montalescot G, et al. Lancet 2009;373:723-31

Major efficacy and safety endpoints at 30 days Montalescot G, et al. Lancet 2009;373:723-31

Major efficacy and safety endpoints at 15 months Montalescot G, et al. Lancet 2009;373:723-31

Kaplan-Meier curves for selected endpoints Montalescot G, et al. Lancet 2009;373:723-31